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ABSTRACT
Background: Original studies published over the last decade regarding time trends in dementia report mixed
results. The aims of the present study were to use linked administrative health data for the province of
Saskatchewan for the period 2005/2006 to 2012/2013 to: (1) examine simultaneous temporal trends in annual
age- and sex-specific dementia incidence and prevalence among individuals aged 45 and older, and (2) stratify
the changes in incidence over time by database of identification.
Methods: Using a population-based retrospective cohort study design, data were extracted from seven
provincial administrative health databases linked by a unique anonymized identification number. Individuals
45 years and older at first identification of dementia between April 1, 2005 and March 31, 2013 were
included, based on case definition criteria met within any one of four administrative health databases
(hospital, physician, prescription drug, and long-term care).
Results: Between 2005/2006 and 2012/2013, the 12-month age-standardized incidence rate of dementia
declined significantly by 11.07% and the 12-month age-standardized prevalence increased significantly by
30.54%. The number of incident cases decreased from 3,389 to 3,270 and the number of prevalent cases
increased from 8,795 to 13,012. Incidence rate reductions were observed in every database of identification.
Conclusions: We observed a simultaneous trend of decreasing incidence and increasing prevalence of dementia
over a relatively short 8-year time period from 2005/2006 to 2012/2013. These trends indicate that the average
survival time of dementia is lengthening. Continued observation of these time trends is warranted given the
short study period.
Key words: dementia, diagnosis, epidemiology, physician, hospital, long-term care, prescription drug, administrative data
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Introduction
Dementia refers to a “clinical syndrome of cognitive
decline” that interferes with daily functioning
and generally occurs alongside behavior and
personality changes; the decline must not be
the result of delirium or another condition (i.e.
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medical, neurological, or psychiatric) (Chertkow
et al., 2013). The most common causes of
dementia are Alzheimer’s disease (50–75%), vas-
cular dementia (20–30%), frontotemporal demen-
tia (5–10%), and dementia with Lewy bodies
(<5%) [Alzheimer’s Disease International (ADI),
2014]).
The estimated global number of incident and
prevalent cases of dementia in 2015 was 9.9
million and 46.8 million respectively (ADI, 2015).
Worldwide, the age- and gender-standardized
incidence of dementia among adults aged 60–
64 was an estimated 3.9 per 1,000 person years,
doubling with every 6.3 years of age to 104.8
per 1,000 person years among adults aged 90
and older (ADI, 2015). High income countries
generally exhibited higher incidence than low
and middle income countries, particularly across
older age groups. Furthermore, the estimated age-
standardized prevalence of dementia ranged from
1.3% among those aged 60–64 to 27.1% in those
aged 90 and older in Central Europe (4.7% aged 60
and older), and from 2.2% among those aged 60–
64 to 29.4% in those aged 85 and older in North
Africa/Middle East (8.7% aged 60 and older) (ADI,
2015).
Original studies published over the last decade
regarding time trends in dementia have reported
mixed results in several different regions of the
world. Key studies provide evidence of declining
incidence in Rochester, United States (US) (Rocca
et al., 2011) and Rotterdam, the Netherlands
(Schrijvers et al., 2012). Further studies indicate
stable (Hall et al., 2009) or declining dementia
prevalence in a national US sample (Langa
et al., 2008), stable prevalence in a German
sample (Doblhammer et al., 2015), and declining
prevalence in Zaragoza, Spain (Lobo et al., 2007)
and regions of England and Wales (Matthews
et al., 2013). In contrast, other research reveals
increasing dementia prevalence in northern Sweden
(Mathillas et al., 2011), a national sample of France
(Bertrand et al., 2013), Hisayama, Japan (Sekita
et al., 2010), and the province of Alberta, Canada
(Jacklin et al., 2013). Notably, the number of
prevalent dementia cases is forecast to increase to
a greater extent in low and middle (227–264%)
versus high income countries (116%) by 2050
(ADI, 2015).
To the best of our knowledge, two other
original studies that examined simultaneous trends
in dementia incidence and prevalence have been
published within the last 10 years (Qiu et al.,
2013; Ng et al., 2015). In the first, a prospective
cohort study of two 6-year cohorts aged 75
and older from 1987–1989 and 2001–2004 in
central Stockholm, Sweden, Qiu et al. (2013)
found that age-standardized dementia prevalence
remained stable. Dementia incidence was not
assessed directly; however, survival time based
on 6-year follow-up was significantly longer for
the later than earlier cohort, leading Qiu and
colleagues to suggest that incidence decreased over
the study period. In the second, a report based
on a retrospective administrative health data study
of the population aged 40 and older in Ontario,
Canada, Ng et al. (2015) concluded that age-and
sex-adjusted dementia prevalence increased over a
7-year period between 2004/2005 and 2010/2011,
from 16.3 to 19.7 per 1,000 persons, and age- and
sex-adjusted incidence decreased from 5.1 to 5.0
per 1,000 persons.
The value of using administrative health data
to examine temporal trends in dementia incidence
and prevalence can be illustrated in three key
ways. The first of these is the investigation of
possible impacts of population-level trends in
modifiable risk factors throughout the lifecourse
(early, midlife, and late life), on the incidence and
prevalence of dementia (ADI, 2014). Currently,
moderate to robust evidence exists for four domains
of modifiable dementia risk factors: developmental
(e.g. occupational status, education), psychological
(e.g. depression, anxiety, sleep disorders), lifestyle
or behavior (e.g. cigarette use), and cardiovascular
(e.g. obesity, cholesterol, hypertension, diabetes)
(ADI, 2014). Downward trends in dementia in-
cidence over time in populations with documented
improvements in these risk factors (e.g. improved
education levels and reduced hypertension) would
provide further evidence of the association between
dementia and these risk factors. The second use of
administrative health data in secular trend studies
is to provide evidence for the association between
trends in dementia and other population-level
trends and interventions, including demographics
(e.g. aging; Langa et al., 2008; Sekita et al., 2010);
life expectancy (Schrijvers et al., 2012; Qiu et al.,
2013); treatment of chronic diseases (e.g. use of
statins; Langa et al., 2008; Hall et al., 2009;
and hypertensive medications; Langa et al., 2008);
treatment of cardiovascular diseases (Mathillas
et al., 2011; Schrijvers et al., 2012); health and
social care for individuals with dementia (Sekita
et al., 2010; Mathillas et al., 2011); and standard
of living (Langa et al., 2008). Third, current
dementia projection methods are typically based
on the assumption that certain factors will remain
stable over time, such as age-specific dementia
prevalence (ADI, 2015), mortality, and dementia
risk factors (except demographics) (Rocca et al.,
2011). Such projections do not adequately account
for “changing patterns in risk factors” (Norton
et al., 2013), i.e. trends in population-level factors,
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that can be accounted for in studies based on
administrative health data.
There have been several recent original Cana-
dian studies concerning dementia prevalence, at
the provincial level (Fransoo et al., 2009; Martens
et al., 2010; Gill et al., 2011; Chartier et al.,
2012; Jacklin et al., 2013). However, there have
been few Canadian studies of trends in dementia
prevalence (Jacklin et al., 2013; Ng et al., 2015) and
incidence (CSHA 2000; Tyas et al., 2006; Ng et al.,
2015). Using linked administrative health data for
the province of Saskatchewan for the time period
between 2005/2006 and 2012/2013, the purposes
of this study were to: (1) examine simultaneous
age- and sex-specific temporal trends in dementia
incidence and prevalence among individuals aged
45 and older, and (2) stratify any changes in
incidence over time by database of identification.
Methods
Setting
The province of Saskatchewan is the middle
of three Canadian prairie provinces and covers
651,000 km2 (Saskatchewan Bureau of Statistics,
2015). Between 2006 and 2013, the province’s
population grew 116,021 (11.7%) from 992,302
to 1,108,303 (Statistics Canada, 2014a). The
proportion of the population aged 45–64 grew
from 25.1% to 26.1% while the proportion aged
65 and older declined from 15% to 14.4%. The
province’s population growth of 74,047 between
2006 and 2011 (Saskatchewan Bureau of Statistics,
2014) was largely attributable to interprovincial
migration (12,000; 16.2%) and immigration
(28,000; 37.8%), with three times more immigrants
during this period compared to 2001–2006 (9,800)
(Statistics Canada, 2012). Among the 13 provinces
and territories, Saskatchewan’s growth during
2006–2011 was third largest at 6.7%, and larger
than the national average at 5.9% (Statistics
Canada, 2012).
Nearly all (99%) Saskatchewan residents receive
provincial healthcare coverage (Downey et al.,
2005) and constitute the “covered population”
for the present study. Federally insured residents
(federal prison inmates, members of the Canadian
Forces, and Royal Canadian Mounted Police)
are not included in the covered population
(SaskatchewanMinistry of Health, 2012); however,
their information is captured in hospital data. The
Registered Indian population is not covered by the
province’s Prescription Drug Plan (Saskatchewan
Ministry of Health, 2010) and therefore are
not included in the Prescription Drug Database
employed in the current study. Approximately 13%
of the Saskatchewan population in 2012 were
classified as Registered Indians (Aboriginal Affairs
and Northern Development Canada, 2013).
Data sources
Data were extracted from seven provincial ad-
ministrative health databases linked by a unique
anonymized personal health services number
(Saskatchewan Ministry of Health, 2010). Data-
bases describing the demographic characteristics
and insurance coverage for the population of
Saskatchewan included the Person Health Regis-
tration System, Saskatchewan Resident Geography
Database, and the Vital Statistics database. The
databases from which the cohort were identified
were the Hospital Discharge Abstract Database,
Physician Services Claims Database, Prescription Drug
Database, and the Resident Assessment Instrument –
Minimum Data Set (RAI-MDS), i.e. Long-term Care
Database.
From 2002 onwards, the Hospital Discharge
Abstract Database includes 5-digit ICD-10-CA
codes to record up to 25 diagnoses per re-
cord. The Physician Services Claims Database
includes information used by physicians to claim
payment from the provincial government for
services provided to patients and a 3-digit ICD-
9 diagnosis code associated with the service
(maximum of one diagnosis code per service claim)
(Saskatchewan Ministry of Health, 2010). The
Prescription Drug Database includes information
about drugs dispensed such as classification of the
drug and drug identification number (DIN), with
only Saskatchewan Formulary drugs eligible for
coverage. The Long-term Care Database contains
assessment information collected at admission
to a residential care facility, at regular three-
month intervals, and upon significant changes in
clinical status (Morris et al., 2010). Admission and
quarterly assessment data were included in the
present study.
Cohort
The case definition algorithm in the present study
was developed over a three-stage process. Further
details regarding the algorithm used in the current
study are available elsewhere (Kosteniuk et al.,
2015).
Individuals aged 45 years or older at their first-
ever recorded identification of dementia between
April 1, 2005 and March 31, 2013 constituted the
cohort. “Young onset dementia” (i.e. before age
of 65) is estimated to affect approximately 6–9%
of all prevalent cases (WHO, 2012) yet the true
prevalence is unknown because epidemiological
studies of dementia generally exclude those younger
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than 65 years (Lambert et al., 2014). Given
the distinct needs and experiences of individuals
with young onset dementia and their families
and the deficiency of research in this area
(Ducharme et al., 2014), as well as the need for a
complete epidemiological picture, we chose to
employ an age cut-off of 45 in the present study.
A “washout” period of 5 years prior to the
first identification of dementia was used to ensure
that we correctly identified incident dementia.
Individuals entered the cohort either on their index
date or April 1, 2005, whichever was later. They
remained in the cohort until the earliest occurrence
of any of the following: death, loss of their insurance
(i.e. gap in insurance coverage of more than 3 days),
or March 31, 2013. Individuals with a gap in their
insurance of more than 3 days were not re-entered
into the cohort.
Individuals were identified as a dementia case
if they met at least one of the following criteria:
>1 physician visit (ICD-9 codes 290, 294, 331,
797); >1 hospitalization (ICD-10-CA codes F00,
F01, F02, F03, F04, F05.1, F06.8, F06.9, F09,
F10.6, F10.7, F18.6, F18.7, F19.6, F19.7, G30,
G31.0, G31.1, G91, R54); >1 prescription for a
cholinesterase inhibitor (Aricept DINs 02232043,
02232044; Exelon DINs: 02242115–02242118,
02245240; Reminyl DINs: 02244298–02244300,
02266717, 02266725, 02266733); or – in the Long-
term Care Database – a Cognitive Performance
Scale (CPS) score of 2 or over and/or a disease
category of Alzheimer’s disease or dementia other
than Alzheimer’s disease.
Physician and hospital data are commonly
used in administrative health data studies of
dementia epidemiology, requiring at minimum
one physician visit or hospitalization to identify
a dementia case (Fransoo et al., 2009; Martens
et al., 2010; Gill et al., 2011; Chartier et al., 2012;
Manitoba Centre for Health Policy, 2012; Jacklin
et al., 2013). Alzheimer’s disease does not have
a diagnostic test for confirmation purposes (St
Germaine-Smith et al., 2012) and underdiagnosis
of dementia is a significant problem (Boustani
et al., 2003; ADI, 2011; Connolly et al., 2011).
Therefore, the case definition for the present study
prioritized sensitivity over specificity by including
prescription drug and long-term care data to
account for dementia cases that may not have
been identified in physician or hospital data. Other
medications may be used to treat Alzheimer’s
disease (e.g. memantine); however, the three
medications included in the present study (Aricept,
Exelon, and Reminyl) are the only cholinesterase
inhibitors prescribed in Canada (Lee et al., 2011)
and are the most commonly used treatment of
Alzheimer’s disease in the country (Hogan, 2014).
Moreover, cholinesterase inhibitors are typically
not used for the treatment of other conditions
and have been shown to have limited value in the
treatment of attention-deficit hyperactivity disorder
in a recent review (Bidwell et al., 2011).
In the Long-term Care Database, the CPS
consists of five measures in total: one of comatose
status, two cognition (short term memory and
cognitive skills for daily decision making), one
communication, and one measure of activities
of daily living (Morris et al., 1994). The CPS
categorizes individuals into one of seven levels
of cognitive performance based on a score of
0 to 6 (Intact = 0; 1 = Borderline intact;
2 = Mild impairment; 3 = Moderate impairment;
4 = Moderate severe impairment; 5 = Severe
impairment; 6 = Very severe impairment). A
CPS score of 2 or higher is equivalent to an
average Mini-Mental State Examination score of
19 or lower (Bartfay et al., 2013). This cut-
off indicates dementia at the moderate to severe
stage (Perneczky et al., 2006) and possible mild
to very severe impairment (Morris et al., 1994).
A CPS score of 2 or higher has been validated
against physician diagnosis and found to be 68%
sensitive and 92% specific in detecting dementia
(Travers et al., 2013), and against the Cambridge
Examination for Mental Disorders of the Elderly-
Revised (CAMDEX-R) and found to be 81%
sensitive and 80% specific in detecting cognitive
impairment (Paquay et al., 2007).
Independent variables
Age, sex, and administrative health database of first
identification were the three independent variables
included in the analysis. Age was represented by
the categories of 45–54, 55–64, 65–74, 75–84, and
85 years and older. The four administrative health
datasets included hospital, physician, prescription
drug, and long-term care.
Statistical analysis
The age structure of the total cohort was used
to adjust the sex-specific incidence rates and
prevalence for age, and 95% confidence intervals
(CI) were calculated for all crude and age-
standardized rates.
Incident cases were identified for each 12-month
period between April 1, 2005 and March 31,
2013. Incident cases met the case definition criteria
and had not been previously identified during
the washout period between April 1, 2000 and
March 31, 2005. The numerator for each 12-
month incidence rate was the number of people
alive on April 1 of each year, who also met the
case definition of dementia between April 1 of
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Figure 1. Age-standardized 12-month incidence rate of dementia among adults 45 years of age and older, Saskatchewan, from
2005/2006 to 2012/2013.
that year and March 31 of the following year.
The denominator was the population at risk of
developing incident dementia (i.e. after removing
individuals with prevalent dementia for the same
period, the remaining were aged 45 years or older
on April 1 of each year with at least one day
of health insurance coverage for the 12-month
period).
Prevalent cases met the case definition criteria
for each 12-month period from April 1 to March
31 for the years 2005 to 2013. The numerator
for each 12-month prevalence was the number of
people alive on April 1 of each year who met
the case definition criteria at any time prior to
April 1 of that year. Those individuals at risk
for prevalent dementia (i.e. all individuals in the
covered population aged 45 years or older on
April 1 of each year with at least one day of
health insurance coverage for the 12-month period)
constituted the denominator.
For incidence and prevalence, we calculated
the percentage changes between 2005/2006 and
2012/2013 in absolute number (n), percentage,
population, and age-standardized rate per 1,000,
by dividing the difference between the two figures
by the earlier figure and multiplying by 100.
Percentage changes in age-standardized incidence
rates and prevalence per 1,000 were compared for
significant differences (p < 0.05) using the χ2 test,
and 95% CI were calculated for all crude and
age-standardized rates. All analyses were completed
with SAS 9.3 (SAS Institute Inc, Cary NC).
Ethical considerations
The University of Saskatchewan Biomedical Re-
search Ethics Board granted ethics approval for this
study (Bio-REB #12-339).
Results
Incidence
As shown in Figure 1, the overall age-standardized
incidence rate of dementia among individuals 45
years and older declined gradually and steadily
from 2005/2006 until 2010/2011, rising slightly in
2011/2012 before dropping again in 2012/2013.
Table 1 indicates that the annual population
rose steadily each year between 2005/2006 to
2012/2013. As shown in Table 2, the population
increased by 11.38% from 403,123 to 449,012
while the absolute number of overall incident cases
dropped by 3.51% from 3,389 to 3,270 between
2005/2006 and 2012/2013. The overall age-
standardized incidence rate declined significantly
by 11.07% (p < 0.0001) from 8.41 to 7.48 per
1,000 over the 8-year period.
Table 2 shows that although the female and
male populations increased between 2005/2006
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Table 1. Twelve-month incidence and prevalence of dementia among adults 45 years of age and older, Saskatchewan, from 2005/2006 to 2012/2013
2005/2006 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 2011/2012 2012/2013
............................................................................................................................................................................................................................................................................................................................................................................................................................................................
Incidence
Total population at risk 403,123 407,409 417,605 426,839 431,628 438,941 445,187 449,012
Incident cases 3,389 3,338 3,314 3,312 3,320 3,346 3,475 3,270
Crude incidence
Female 9.77 (9.35–10.20) 9.66 (9.24–10.08) 9.25 (8.85–9.67) 9.05 (8.66–9.46) 8.80 (8.41–9.20) 8.88 (8.49–9.27) 8.89 (8.51–9.28) 8.25 (7.88–8.63)
Male 6.96 (6.59–7.34) 6.64 (6.28–7.00) 6.54 (6.19–6.90) 6.40 (6.06–6.75) 6.53 (6.19–6.88) 6.31 (5.98–6.65) 6.68 (6.34–7.03) 6.28 (5.95–6.62)
Overall 8.41 (8.13–8.69) 8.19 (7.92–8.47) 7.94 (7.67–8.21) 7.76 (7.50–8.03) 7.69 (7.43–7.96) 7.62 (7.37–7.88) 7.81 (7.55–8.07) 7.04 (7.04–7.54)
Age-standardized incidence rate (to 2005/2006 total Sask. population)
Female 8.31 (7.95–8.68) 8.26 (7.91–8.63) 8.00 (7.65–8.36) 7.90 (7.56–8.26) 7.72 (7.38–8.07) 7.75 (7.42–8.10) 7.79 (7.46–8.14) 7.23 (6.91–7.56)
Male 8.56 (8.11–9.02) 8.20 (7.76–8.66) 8.19 (7.75–8.64) 8.05 (7.63–8.50) 8.23 (7.80–8.67) 7.95 (7.53–8.39) 8.38 (7.96–8.82) 7.84 (7.43–8.26)
Overall 8.41 (8.13–8.69) 8.24 (7.96–8.52) 8.07 (7.80–8.35) 7.96 (7.69–8.24) 7.92 (7.65–8.19) 7.83 (7.57–8.10) 8.03 (7.76–8.30) 7.48 (7.22–7.74)
Prevalence
Total population at risk 411,918 417,297 428,269 438,069 443,466 451,222 457,822 462,024
Prevalent cases 8,795 9,888 10,664 11,230 11,838 12,281 12,635 13,012
Crude prevalence
Female 26.00 (25.33–26.68) 28.84 (28.14–29.55) 30.47 (29.76–31.19) 31.46 (30.74–32.19) 32.87 (32.14–33.61) 33.32 (32.60–34.06) 33.79 (33.06–34.53) 34.19 (33.46–34.93)
Male 16.36 (15.81–16.93) 18.16 (17.58–18.76) 18.94 (18.36–19.54) 19.42 (18.84–20.02) 20.12 (19.53–20.72) 20.74 (20.15–21.35) 21.06 (20.47–21.67) 21.82 (21.22–22.43)
Overall 21.35 (20.91–21.80) 23.70 (23.24–24.16) 24.90 (24.44–25.37) 25.64 (25.17–26.11) 26.69 (26.22–27.17) 27.22 (26.74–27.70) 27.60 (27.13–28.08) 28.16 (27.69–28.64)
Age-standardized prevalence (to 2005/2006 total Sask. population)
Female 21.88 (21.31–22.45) 24.04 (23.45–24.63) 25.04 (24.85–26.05) 26.35 (25.75–26.96) 27.37 (26.77–27.99) 27.59 (26.99–28.20) 28.04 (27.44–28.65) 28.33 (27.73–28.94)
Male 20.51 (19.81–21.22) 22.65 (21.92–23.39) 23.81 (23.07–24.86) 24.53 (23.80–25.29) 25.35 (24.60–26.10) 26.06 (25.31–26.82) 26.31 (25.57–27.07) 27.15 (26.40–27.91)
Overall 21.35 (20.91–21.80) 23.50 (23.05–23.97) 24.82 (24.35–25.29) 25.65 (25.19–26.13) 26.60 (26.13–27.07) 27.00 (26.53–27.48) 27.37 (26.90–27.85) 27.87 (27.40–28.35)
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Table 2. Change in 12-month incidence of dementia among adults 45 years of age and older, Saskatchewan, 2005/2006 to 2012/2013
2005/2006 N = 3,389 2012/2013 N = 3,270 change from 2005/2006 to 2012/2013 (%)
age-stand.
age-standardized age-standardized rate per
n % population crude rate per 1,000 rate per 1,000 n % population crude rate per 1,000 rate per 1 ,000 n % population 1,000 p valuea
.........................................................................................................................................................................................................................................................................................................................................................................................................................................................
Female 2,030 59.89 207,766 9.77 (9.35–10.20) 8.31 (7.95–8.68) 1,887 57.71 228,782 8.25 (7.88–8.63) 7.23 (6.91–7.56) −7.04 −3.64 10.12 −12.97 < 0.0001
Male 1,359 40.10 195,357 6.96 (6.59–7.34) 8.56 (8.11–9.02) 1,383 42.29 220,230 6.28 (5.95–6.62) 7.84 (7.43–8.26) 1.77 5.46 12.73 − 8.39 0.0072
Database
Physician 1,023 30.19 403,123 2.54 n/a 979 29.94 449,012 2.18 n/a −4.30 −0.83 11.38 −14.17b 0.0007
Hospital 964 28.44 403,123 2.39 n/a 933 28.53 449,012 2.08 n/a −3.22 0.32 11.38 −12.97b 0.0022
Prescription Drug 204 6.02 403,123 0.51 n/a 214 6.54 449,012 0.48 n/a 4.90 8.64 11.38 − 5.88b 0.5376
LTC 1,198 35.35 403,123 2.97 n/a 1,144 34.98 449,012 2.55 n/a −4.51 −1.05 11.38 −14.14b 0.0002
Female
45–54 35 1.72 75,340 0.46 (0.32–0.65) 0.47 (0.32–0.65) 37 1.96 75,597 0.49 (0.34–0.67) 0.46 (0.32–0.63) 5.71 13.95 0.34 − 1.46 0.8249
55–64 60 2.96 51,927 1.16 (0.88–1.49) 1.15 (0.88–1.48) 85 4.50 67,958 1.25 (1.00–1.55) 1.23 (0.99–1.53) 41.67 52.03 30.87 7.16 0.6390
65–74 178 8.77 36,476 4.88 (4.19–5.65) 4.85 (4.17–5.62) 165 8.74 42,193 3.91 (3.34–4.55) 4.10 (3.50–4.78) −7.30 −0.34 15.67 −15.40 0.0396
75–84 656 32.32 29,487 22.25 (20.59–24.00) 21.91 (20.28–23.63) 539 28.56 27,767 19.41 (17.82–21.10) 19.03 (17.47–20.69) − 17.84 − 11.63 − 5.83 −13.15 0.0177
85+ 1,101 54.24 14,536 75.74 (71.49–80.16) 74.53 (70.35–78.88) 1,061 56.22 15,267 69.50 (65.51–73.65) 65.61 (61.85–69.53) −3.63 3.65 5.03 −11.97 0.0377
All ages 2,030 100.00 207,766 9.77 (9.35–10.20) 8.31 (7.95–8.68) 1,887 100.00 228,782 8.25 (7.88–8.63) 7.23 (6.91–7.56) −7.04 0 10.12 −12.97 < 0.0001
Male
45–54 42 3.09 77,416 0.54 (0.39–0.73) 0.54 (0.39–0.73) 33 2.39 77,592 0.43 (0.29–0.60) 0.40 (0.27–0.56) − 21.43 − 22.65 0.23 −26.24 0.294
55–64 74 5.45 52,879 1.40 (1.10–1.76) 1.40 (1.10–1.76) 92 6.65 69,958 1.32 (1.06–1.61) 1.30 (1.59–1.05) 24.32 22.02 32.30 − 7.51 0.6903
65–74 178 13.10 34,121 5.22 (4.48–6.04) 5.25 (4.51–6.08) 164 11.86 41,005 4.00 (3.41–4.66) 4.25 (3.63–4.96) −7.87 −9.47 20.18 −18.97 0.0136
75–84 499 36.72 23,228 21.48 (19.66–23.43) 21.91 (20.05–23.89) 475 34.35 22,849 20.79 (18.98–22.72) 20.86 (1905–22.80) −4.81 −6.45 − 1.63 − 4.77 0.6046
85+ 566 41.65 7,713 73.38 (67.66–79.43) 75.70 (69.79–81.93) 619 44.76 8,826 70.13 (64.89–75.66) 71.46 (66.12–77.09) 9.36 7.47 14.43 − 5.60 0.4201
All ages 1,359 100 195,357 6.96 (6.59–7.34) 8.56 (8.11–9.02) 1,383 100.00 220,230 6.28 (5.95–6.62) 7.84 (7.43–8.26) 1.77 0 12.73 − 8.39 0.0072
Overall
45–54 77 2.27 152,756 0.50 (0.40–0.63) 0.50 (0.40–0.63) 70 2.14 153,189 0.46 (0.36–0.58) 0.43 (0.33–0.54) −9.09 −5.73 0.28 −14.96 0.5521
55–64 134 3.95 104,806 1.28 (1.07–1.51) 1.28 (1.07–1.51) 177 5.41 137,916 1.28 (1.10–1.49) 1.27 (1.09–1.47) 32.09 36.96 31.59 − 0.91 0.9737
65–74 356 10.50 70,597 5.04 (4.53–5.59) 5.04 (4.53–5.59) 329 10.06 83,198 3.95 (3.54–4.40) 4.18 (3.74–4.65) −7.58 −4.19 17.85 −17.16 0.0014
75–84 1,155 34.08 52,715 21.91 (20.68–23.20) 21.91 (20.68–23.20) 1,014 31.01 50,616 20.03 (18.83–21.29) 19.85 (18.66–21.09) − 12.21 −9.01 − 3.98 − 9.42 0.0354
85+ 1,667 49.19 22,249 74.92 (71.50–78.46) 74.92 (71.50–78.46) 1,680 51.38 24,093 69.73 (66.55–73.02) 67.65 (64.56–70.84) 0.78 4.45 8.29 − 9.70 0.0309
All ages 3,389 100 403,123 8.41 (8.13–8.69) 8.41 (8.13–8.69) 3,270 100 449,012 7.28 (7.04–7.54) 7.48 (7.22–7.74) −3.51 0 11.38 −11.07 < 0.0001
aTest of difference between age-standardized dementia incidence rate in 2005/2006 versus 2012/2013.
bChange in crude rate per 1,000.
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Figure 2. Age-standardized 12-month prevalence of dementia among adults 45 years of age and older, Saskatchewan, from 2005/2006
to 2012/2013.
and 2012/2013 (10.12% and 12.73% respectively),
the absolute number of incident cases among
females dropped while the absolute number of
incident cases among males rose. Consequently,
the age-standardized incidence rate decreased more
markedly among females than males, dropping
significantly by 12.97% (p < 0.0001) among
females (from 8.31 to 7.23 per 1,000) compared
to 8.39% (p = 0.0072) among males (from 8.56
to 7.84 per 1,000). The proportion of incident
cases attributed to females versus males dropped
as well, by 3.66% from 59.89% to 57.71%. The
age-standardized incidence rate was slightly higher
among males than females in 2005/2006 (8.56 vs.
8.31 per 1,000) and remained so in 2012/2013
(7.84 vs. 7.23 per 1,000).
Overall mean age at identification in 2005/2006
(81.67 + 9.98 years) did not change significantly
(p = 0.24) in 2012/2013 (81.97 + 10.70 years).
As shown in Table 2, the population changed most
substantially in the 55–64 and 65–74 age groups,
increasing 16–31% among females and 20–32%
among males. Despite this, the age-standardized
incidence rate in the 55–64 age group did not
change significantly over time for either sex. Among
females, significant declines in age-standardized
incidence rates were apparent in the three oldest
age groups, ranging from 11.97% (p = 0.0377) in
those aged 85 and older [from 74.53 to 65.61 per
1,000 to 15.40% (p = 0.0396) in those aged 65–74
(from 4.85 to 4.10 per 1,000)]. A significant decline
of 18.97% (p = 0.0136) in the age-standardized
incidence rate among males was apparent only
among those aged 65–74 (from 5.25 to 4.25
per 1,000). The population remained stable and
neither sex in the 45–54 age group experienced
significant changes in age-standardized incidence
rates over time.
In terms of the databases where incident cases
of dementia were first identified, the greatest
proportion were first identified in Long-term Care
in 2005/2006 (35.35%) and 2012/2013 (34.98%)
(Table 2). The declines over time in the crude
incidence rates per 1,000 were significant across
every database with the exception of Prescription
Drug, with similar declines in the Physician
(14.17%; p = 0.0007), Long-term Care (14.14%;
p = 0.0002) and Hospital databases (12.97%; p =
0.0022).
Prevalence
Figure 2 shows that the overall age-standardized
prevalence of dementia among those aged 45 and
older increased between 2005/2006 to 2012/2013.
Most of the increase took place in the first
four years of the study period, with the upward
trend slowing between 2009/2010 and 2012/2013.
Over the 8-year period, the absolute number of
overall prevalent cases rose 47.95% from 8,795
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to 13,012, compared to an increase of 12.16% in
the population from 411,918 to 462,024 (Tables 1
and 3). The overall age-standardized prevalence
increased significantly (p < 0.0001) by 30.54% over
time from 21.35 to 27.87 per 1,000.
As shown in Table 3, the population increased
slightly more among males than females (13.36%
vs. 11.05%), as did the absolute number of
prevalent cases (51.22% vs. 46.03%). As a
result, the age-standardized prevalence increased
significantly (p < 0.0001) in both sexes, but to
a slightly greater degree by 32.38% among males
(from 20.51 to 27.15 per 1,000) compared to
29.48% among females (from 21.88 to 28.33
per 1,000). The proportion of prevalent cases
attributed to males relative to females rose as well,
from 36.94% to 37.76% (2.33%). However, the
age-standardized incidence rate was slightly higher
among females than males in 2005/2006 (21.88 vs.
20.51 per 1,000) and remained so in 2012/2013
(28.33 vs. 27.15 per 1,000).
Similar to increases in the population at risk
for incident cases, the largest increases in the
population at risk for prevalent cases took place
in the 55–64 and 65–74 age groups. With the
exception of the 45–54 age group, significant
increases in age-standardized prevalence were
apparent in every age group for both sexes. The
largest increase in the age-standardized prevalence
for both sexes took place in the 55–64 age group
(107.08% female, p < 0.0001; 48.72% male, p <
0.0001) and the smallest increase was experienced
by the 85 and older age group (23.98% female, p <
0.0001; 23.86% male; p < 0.0001).
Discussion
Using a population-based retrospective cohort
design, we identified incident and prevalent cases
of dementia between April 1, 2005 and March
31, 2013 in linked administrative health databases
(Hospital Discharge Abstracts, Physician Service
Claims, Prescription Drug, and RAI- MDS, i.e.
Long-term Care), among individuals 45 years and
older at first identification of dementia.
Considering the first study objective to invest-
igate simultaneous age- and sex-specific temporal
trends in dementia incidence and prevalence, we
found the overall age-standardized incidence rate
declined significantly by 11.07% and the age-
standardized prevalence increased significantly by
30.54% over the 8-year study period. Overall, the
incidence rate declined from 8.41 to 7.48 per
1,000 despite an 11.38% increase in the overall
population. Although both sexes experienced
significant declines in the incidence rate over time,
females experienced a slightly larger decrease than
males (12.97% vs. 8.39%). The age-standardized
incidence rate remained higher among males than
females in 2012/2013 (7.84 vs. 7.23 per 1,000) as
in 2005/2006 (8.56 vs. 8.31 per 1,000). Among
females, significant decreases occurred only in the
three oldest age groups, with the largest decline in
the 65–74 age group. Among males, only the 65–74
age group experienced a significant decline over the
8-year period.
Overall, the age-standardized prevalence of
dementia increased significantly by 30.54% from
21.35 to 27.87 per 1,000, and the population
increased by 12.16% between 2005/2006 and
2012/2013. Males experienced a slightly larger
increase than females in the age-standardized
prevalence over time (32.38% vs. 29.48%). The
age-standardized prevalence was higher among
females than males in 2005/2006 (21.88 vs. 20.51
per 1,000) and remained so in 2012/2013 (28.33
vs. 27.15 per 1,000). Significant increases were
apparent in every age group for both sexes (except
those 45–54), with the largest increment in the 55–
64 age group and the smallest increment in the 85
and older age group for both sexes.
Considering the second study objective to
stratify the changes in incidence over the 8-
year study period by database of identification,
significant decreases in the crude incidence rate
per 1,000 were apparent in 3 of the 4 databases
examined, with declines of 13–14% across Hospital
Discharge Abstracts, Physician Service Claims, and
RAI-MDS (i.e. Long-term Care).
Incidence
Our finding of declining dementia incidence over
time is consistent with four original studies
published within the last 10 years on the topic of
incidence trends. Two were separate field studies
(i.e. two-phase studies with screening followed
by a structured clinical evaluation) in Rotterdam,
the Netherlands (Schrijvers et al., 2012) and
Stockholm, Sweden (Qiu et al., 2013); the third
study was based on medical records in Rochester,
US (Rocca et al., 2011) and the most recent study
was based on administrative health data from the
province of Ontario, Canada (Ng et al., 2015).
Compared to a 1.4% per year decline in the current
study, incidence rates declined an average of 2.5–
3% per year in two of the four studies (Rocca et al.,
2011; Schrijvers et al., 2012), approximately 4.2%
over a 7-year period in a third study (Ng et al.,
2015), and an unspecified amount in a fourth study
(Qiu et al., 2013). Similar to the present study,
Schrijvers et al. (2012) observed a slightly greater
decrease in the incidence rate over time in females
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Table 3. Change in 12-month prevalence of dementia among adults 45 years of age and older, Saskatchewan, 2005/2006 to 2012/2013
2005/2006 n = 8,795 2012/2013 n = 13,012 change from 2005/2006 to 2012/2013 (%)
age-stand.
crude prevalence age-standardized crude prevalence age-standardized prevalence
n % population per 1 ,000 prevalence per 1 ,000 n % population per 1 ,000 prevalence per 1 ,000 n % population per 1 ,000 p valuea
.........................................................................................................................................................................................................................................................................................................................................................................................................................................................
Female 5,546 63.06 213,312 26.00 (25.33–26.68) 21.88 (21.21–22.45) 8,099 62.24 236,881 34.19 (33.46–34.93) 28.33 (27.73–28.94) 46.03 − 1.36 11.05 29.48 < 0.0001
Male 3,249 36.94 198,606 16.36 (15.81–16.93) 20.51 (19.81–21.22) 4,913 37.76 225,143 21.82 (21.22–22.43) 27.15 (26.40–27.91) 51.22 2.33 13.36 32.38 < 0.0001
Female
45–54 94 1.69 75,434 1.25 (1.01–1.53) 1.25 (01.01–1.53) 110 1.36 75,707 1.45 (1.19–1.75) 1.33 (1.09–1.60) 17.02 −19.53 0.36 6.48 0.2733
55–64 163 2.94 52,090 3.13 (2.67–3.65) 3.12 (2.66–3.64) 446 5.51 68,404 6.52 (5.93–7.15) 6.47 (5.88–7.09) 173.62 87.41 31.32 107.08 < 0.0001
65–74 414 7.46 36,890 11.22 (10.17–12.35) 11.17 (10.13–12.29) 694 8.57 42,887 16.18 (15.01–17.42) 16.79 (15.57–18.07) 67.63 14.88 16.26 50.27 < 0.0001
75–84 1,623 29.26 31,110 52.17 (49.73–54.70) 51.30 (48.90–53.79) 2,034 25.11 29,801 68.25 (65.42–71.18) 66.75 (63.97–69.61) 25.32 −14.18 −4.21 30.11 < 0.0001
85+ 3,252 58.64 17,788 182.82 (177.16–188.58) 179.17 (173.63–184.82) 4,815 59.45 20,082 239.77 (233.88–245.73) 222.14 (216.68–227.66) 48.06 1.38 12.90 23.98 < 0.0001
All ages 5,546 100.00 213,312 26.00 (25.33–26.68) 21.88 (21.21–22.45) 8,099 100.00 236,881 34.19 (33.46–34.93) 28.33 (27.73–28.94) 46.03 0.00 11.05 29.48 < 0.0001
Male
45–54 88 2.71 77,504 1.14 (0.91–1.40) 1.13 (0.91–1.39) 101 2.06 77,693 1.30 (1.06–1.58) 1.19 (0.97–1.45) 14.77 −23.99 0.24 5.39 0.3354
55–64 216 6.65 53,095 4.07 (3.55–4.65) 4.08 (3.55–4.66) 430 8.75 70,388 6.11 (5.55–6.71) 6.06 (5.50–6.66) 99.07 31.58 32.57 48.72 < 0.0001
65–74 438 13.48 34,559 12.67 (11.52–13.91) 12.74 (11.58–13.98) 697 14.19 41,702 16.71 (15.51–17.99) 17.52 (16.25–18.86) 59.13 5.27 20.67 37.54 < 0.0001
75–84 1,153 35.49 24,381 47.29 (44.66–50.03) 48.33 (45.65–51.13) 1,653 33.65 24,502 67.46 (64.35–70.68) 67.66 (64.54–70.89) 43.37 − 5.18 0.50 39.99 < 0.0001
85+ 1,354 41.67 9,067 149.33 (142.06–156.84) 155.55 (147.97–163.36) 2,032 41.36 10,858 187.14 (179.85–194.61) 192.66 (185.15–200.35) 50.07 − 0.74 19.75 23.86 < 0.0001
All ages 3,249 100.00 198,606 16.36 (15.81–16.93) 20.51 (19.81–21.22) 4,913 100.00 225,143 21.82 (21.22–22.43) 27.15 (26.40–27.91) 51.22 0.00 13.36 32.38 < 0.0001
Overall
45–54 182 2.07 152,938 1.19 (1.02–1.38) 1.19 (1.02–1.38) 211 1.62 153,400 1.38 (1.20–1.57) 1.26 (1.10–1.44) 15.93 −21.74 0.30 5.97 0.1512
55–64 379 4.31 105,185 3.60 (3.25–3.98) 3.60 (3.25–3.98) 876 6.73 138,792 6.31 (5.90–6.74) 6.26 (5.86–6.69) 131.13 56.15 31.95 73.77 < 0.0001
65–74 852 9.69 71,449 11.93 (11.14–12.75) 11.93 (11.14–12.75) 1,391 10.69 84,589 16.44 (15.60–17.32) 17.15 (16.26–18.06) 63.26 10.32 18.39 43.77 < 0.0001
75–84 2,776 31.56 55,491 50.03 (48.23–51.87) 50.03 (48.23–51.87) 3,687 28.34 54,303 67.90 (65.80–70.05) 67.16 (65.08–69.28) 32.82 −10.20 −2.14 34.24 < 0.0001
85+ 4,606 52.37 26,855 171.51 (167.02–176.08) 171.51 (167.02–176.08) 6,847 52.62 30,940 221.30 (216.68–225.97) 212.49 (208.06–216.97) 48.65 0.48 15.21 23.89 < 0.0001
All ages 8,795 100.00 411,918 21.35 (20.91–21.80) 21.35 (20.91–21.80) 13,012 100.00 462,024 28.16 (27.69–28.64) 27.87 (27.40–28.35) 47.95 0.00 12.16 30.54 < 0.0001
aTest of difference between age-standardized dementia prevalence in 2005/2006 versus 2012/2013.
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than males; however, in contrast to the present
study, the incidence rate was higher among females
than males at both time points.
Prevalence
The results of five original studies were in line
with our finding of rising dementia prevalence over
time, including separate field studies in Hisayama,
Japan (Sekita et al., 2010) and northern Sweden
(Mathillas et al., 2011) and administrative data
studies in France (Bertrand et al., 2013) and the
Canadian provinces of Alberta (Jacklin et al., 2013)
and Ontario (Ng et al., 2015). At 3.82% per
year, the average annual growth in prevalence in
the present study is in the lower range compared
to other studies, which varied between 1.9–9.8%
(Sekita et al., 2010; Mathillas et al., 2011; Bertrand
et al., 2013; Jacklin et al., 2013; Ng et al., 2015).
In the present study, males experienced a slightly
larger increase than females in prevalence over
time, whereas Sekita et al. (2010) observed the
reverse. However, prevalence remained higher in
females than males over time in the present study,
in line with findings from two studies that observed
increasing prevalence trends (Sekita et al., 2010;
Mathillas et al., 2011).
Contrary to the results from the present
study, three original studies reported a stable
temporal trend in dementia prevalence, including
an administrative health data study in Germany
(Doblhammer et al., 2015) and separate field
studies in Indianapolis, US (Hall et al., 2009)
and Stockholm, Sweden (Qiu et al., 2013).
An additional three original studies reported a
downward temporal trend, namely separate field
studies in a national US sample (Langa et al.,
2008), Zaragoza, Spain (Lobo et al., 2007), and
regions of England and Wales (Matthews et al.,
2013).
Possible explanations
Recently published reviews and commentaries
offer several possible explanations for decreasing
dementia incidence and prevalence over time, as
well as for increasing prevalence (Larson and Langa
2012; Banerjee 2013; Larson et al., 2013; Whalley
and Smyth 2013; ADI, 2015; Lee 2014; Sachev
2014; Wu et al., 2015). Preliminary supporting
evidence for these observations is provided by
findings from several original studies, wherein some
of these explanations were tested directly (Langa
et al., 2008; Hall et al., 2009; Schrijvers et al.,
2012; Elwood et al., 2013; Mathillas et al., 2011),
and others wherein speculations were made on the
basis of population-level trends and interventions
in modifiable risk factors and other factors (e.g.
demographics) (Lobo et al., 2007; Langa et al.,
2008; Sekita et al., 2010; Rocca et al., 2011;
Matthews et al., 2013; Qiu et al., 2013). First,
cognitive reserve as an outcome of higher education
and occupational complexity has been cited as a
protective factor (Langa et al., 2008) and rising
education levels and intellectual demands over
time have been linked to declining incidence and
prevalence of dementia in later cohorts (Langa
et al., 2008; Hall et al., 2009; Rocca et al., 2011;
Schrijvers et al., 2012; Matthews et al., 2013). In
terms of the present study, education levels have
been rising in Saskatchewan, reflected in an annual
2.8% growth in the proportion of post-secondary
graduates aged 25–64 between 2000 and 2012
(Statistics Canada, 2013a).
Recent evidence from a 25-year longitudinal
study supports an association between reduced
risk of dementia and healthy lifestyle or behavior
(e.g. non-smoking, physical activity, healthy diet,
and limited alcohol intake) (Elwood et al., 2013).
Increased uptake of healthy behaviors over time
has been linked to declining dementia trends
(Lobo et al., 2007; Hall et al., 2009; Qiu
et al., 2013) as have reduced cardiovascular risks
such as prevention of heart disease (Matthews
et al., 2013), and decreased hypertension (Qiu
et al., 2013), cholesterol (Qiu et al., 2013),
and stroke (Rocca et al., 2011). However, a
trend of increasing dementia prevalence in Japan
has also been attributed to rising rates of
obesity, hypercholesterolemia, and other metabolic
disorders (Sekita et al., 2010). Population data
indicate that while the rate of non-smoking,
physical activity, and fruit/vegetable consumption
increased in Saskatchewan over the study period, so
too did the rates of obesity, diabetes, and high blood
pressure (Statistics Canada, 2013b; Elliot, 2014).
Recent studies support an association between
temporal trends of dementia decline and improved
treatment of vascular risks (Lobo et al., 2007; Qiu
et al., 2013) such as the use of antithrombotic
and lipid-lowering drugs (Schrijvers et al., 2012),
antihypertensive medications (Langa et al., 2008;
Hall et al., 2009) and statins (Langa et al.,
2008; Hall et al., 2009; Schrijvers et al., 2012).
The most recent available population-level data
for the study period indicate declining annual
rates of mortality in Saskatchewan due to major
cardiovascular diseases (Statistics Canada, 2014b),
heart diseases, and cerebrovascular diseases (2003–
2009) (Statistics Canada, 2013b).
Furthermore, increased dementia prevalence re-
flects lengthier duration of survival with dementia,
possibly owing to improved care and treatment,
such as better health services and institutional care
(Sekita et al., 2010) and increased cholinesterase
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inhibitors prescriptions (Mathillas et al., 2011).
Langa et al. (2008) proposed the “compression
of cognitive morbidity” hypothesis that declining
dementia trends demonstrate a delay of dementia
to older age, reflecting the positive association
over time between quality of life and brain health.
Mathillas et al. (2011) suggested that better
treatment of cardiovascular risks and reduced
mortality due to cardiovascular disease contributed
to a growing pool of Swedish older adults aged 85
and older at risk of dementia, thereby reflecting a
trend of increasing dementia prevalence in this age
cohort.
In terms of the present study, immigration
accounted for 37.8% of total population growth in
Saskatchewan between 2006 and 2011 (Statistics
Canada, 2012). It is plausible that our observation
of declining dementia incidence despite population
growth was partly due to a limited recognition
of dementia during encounters between healthcare
professionals and older adult immigrants to Saskat-
chewan. It is also plausible that health selective
migration, whereby older adult immigrants have
better than average health (Norman et al., 2005),
was partly responsible for this decline.
Variations in the direction and magnitude of
change over time in incidence and prevalence
across studies may be partly due to differences
in diagnostic and classification criteria (Wu et al.,
2014) and sample or population characteristics
(e.g. age cut-offs, demographic trends in popula-
tions). For example, given the higher prevalence
among institutionalized compared to community-
dwelling populations (Hoffman et al., 2014),
excluding nursing home residents in field studies
(e.g. Langa et al., 2008; Hall et al., 2009) possibly
underestimates dementia prevalence overall. Meth-
odological approaches (e.g. observation periods)
may also contribute to variations. For instance, in
comparison to field studies, administrative health
data studies such as the present study tend to
underestimate the true number of individuals with
dementia because dementia tends to be under-
recognized in the healthcare system (Lambert et al.,
2014). Moreover, evidence in some high income
nations of declining incidence trends (Rocca et al.,
2011; Schrijvers et al., 2012; Qiu et al., 2013)
and stable or downward prevalence trends (Lobo
et al., 2007; Langa et al., 2008; Hall et al.,
2009; Matthews et al., 2013; Qiu et al., 2013;
Doblhammer et al., 2015), may reflect a positive
association between national wealth, public health,
and healthcare and therefore hinder generalization
of findings to low and middle income countries
where population aging and cardiovascular risk
factors tend to be on the rise (ADI, 2015; Wu et al.,
2015).
Several interrelated factors potentially account
for the limited impact of the declining dementia
incidence rate on the prevalence of dementia
in the current study. The primary explanation
may be that the 8-year observation period was
too brief to demonstrate an impact. Second,
rising prevalence despite declining incidence in
the present study indicates that survival time
with dementia was also increasing, from 2.56
years in 2005/2006 (21.53/8.41 in 2005/2006) to
3.73 years in 2012/2013 (27.87/7.48). Increased
survival time and prevalence may be due to
identification of dementia in earlier stages (ADI,
2015) and improved treatment after identification.
Lastly, the declining provincial mortality rate
and growth of the overall population aged 45
and older minimized the impact of declining
incidence upon prevalence during the short 8-
year observation period. Beginning in 2009/2010,
declining incidence may have begun to manifest in
a relatively slower increase in prevalence compared
to pre-2009/2010, perhaps signaling the beginning
of a stabilizing trend in dementia prevalence.
Limitations
Administrative health data is collected for purposes
other than disease surveillance, and as such,
several limitations are associated with the use of
administrative health data to determine incidence
and prevalence of dementia. First, underdiagnosis
of dementia is a significant issue, with studies
showing that 31–69% of primary care patients
with dementia do not receive a formal documented
diagnosis (Boustani et al., 2003; Bradford et al.,
2009; van den Dungen et al., 2012). Moreover,
physician services claims permit a maximum of
one diagnosis code per claim, therefore diseases
due to dementia may not be captured in these
claims if patients present with other problems. As a
result, studies based on administrative health data
tend to produce underestimations of prevalence
and incidence in comparison to field studies
(Lambert et al., 2014). However, data linkage
across sectors is possible in administrative health
data studies, allowing community and institution-
dwelling populations to be examined as a whole for
a more complete picture of dementia epidemiology,
in contrast to field studies which may not combine
these populations (e.g. Langa et al., 2008; Hall
et al., 2009). Second, all of the data sources in
the present study included the Registered Indian
population, with the exception of the prescription
drug database. However, Registered Indians who
were not identified as cases in the prescription
drug database were likely identified in one of
the other three administrative health databases.
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Therefore, their exclusion from the prescription
drug database may have contributed to a minor
underestimation of the increase in prevalence over
the study period given the faster rise in dementia
prevalence over time in First Nations compared
to non-First Nations documented by Jacklin and
colleagues (2013). Third, individuals excluded
from the cohort due to interrupted health insurance
coverage (i.e. a gap in insurance coverage of more
than 3 days) accounted for 4.2% of the total cohort
over the study period. Compared to individuals
without gaps, those with gaps were more likely to
be male (40.4% with no gap vs. 45.1% with gap)
and Registered Indian (2.1% with no gap vs. 9.7%
with gap). Registered Indians comprised only 2.4%
of the dementia cohort and therefore the overall
estimates of incidence and prevalence reported in
the present study were not likely affected. However,
despite the small proportion of people excluded
from the study, the sex-specific estimates of preval-
ence were likely to have been affected because of
the additive effect of disproportionately excluding
men. Specifically, each year the prevalence of
dementia will be further underestimated in men
compared to women because each year, just a
few more men than women will be excluded. The
difference in the prevalence of dementia between
men and women will appear more pronounced with
each passing year. Fourth, excluding a prescription
of memantine from the case definition algorithm
may have resulted in a slight underestimation of
prevalence and incidence, in cases that had not
been identified with a cholinesterase prescription
or in one of the other three databases. Finally, our
study period of 8 years may be too short to discern a
consistent and reliable pattern or trend in dementia
over time.
Conclusions
Despite some limitations, administrative health
data is a valuable research tool for tracking
trends in dementia incidence and prevalence. The
present study demonstrated that over an 8-year
period in the province of Saskatchewan, the age-
standardized incidence rate of dementia declined
among individuals aged 45 and older while the
age-standardized prevalence of dementia simultan-
eously increased. These trends indicate that the av-
erage survival time with dementia was also increas-
ing, suggesting the possibilities that recognition of
dementia is taking place in earlier stages and treat-
ment is improving. As individuals live longer with
dementia, similar to other chronic diseases, they
require active care and monitoring for an extended
period of time (Bergman, 2009; ADI, 2014). To
spur improvements in dementia care and address
increasing cost burdens, several G7 nations have
developed national dementia strategies (France,
Japan, United Kingdom, United States, Italy).
Canada currently does not have a national demen-
tia plan, despite an estimated 500,000 Canadians
living with dementia in 2008 and over 100,000
incident cases developing each year (Dudgeon,
2010). Further reduction in dementia incidence
is certainly possible with the type of concentrated
focus that a national strategy promises, and future
research should track these developments.
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